tofacitinib
5 clinical trials
2 products
2 abstracts
6 indications
1 target
Indication
Rheumatoid ArthritisIndication
ulcerative colitisIndication
AneurysmIndication
Behcet's SyndromeIndication
Vascular TypeTarget
Janus kinaseIndication
Sjögren's syndromeAbstract
Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: A case-control study with translational correlates.Org: Departments of Medicine and Oncology, McGill University, Centre de recherche du CHUM, Institut du Cancer de Montréal, Meakins-Christie Laboratories, Department of Medicine, McGill University Health Centre, Division of Cardiology, McGill University,
Clinical trial
Comparative Effectiveness of New Initiators of Tofacitinib and Other Biologic/Targeted Synthetic DMARDs in Patients With Rheumatoid ArthritisStatus: Active (not recruiting), Estimated PCD: 2024-07-15
Clinical trial
Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)Status: Recruiting, Estimated PCD: 2026-08-14
Clinical trial
Advanced Therapeutics in Rheumatoid Arthritis (RA)Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic StudiesStatus: Recruiting, Estimated PCD: 2025-09-21
Clinical trial
Efficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's SyndromeStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Abstract
Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.Org: National Cancer Insititute, Developmental Therapeutics Branch, Nihon Medi-Physics, Epidemiology and Biostatistics, Thoracic and GI Malignancies Branch,
Product
XeljanzProduct
Tofacitinib